An investigational once-weekly oral antiretroviral therapy (ART) combination effectively maintained viral suppression in adults with HIV-1 through 24 weeks, according to a phase IIb study.

The World Health Organization is now recommending that countries include an HIV drug newly approved for prevention, lenacapavir, as a tool in their efforts to fight HIV infections – especially for groups most at risk and in areas where the burden of HIV remains high.

Pharma giant Gilead Sciences agreed to pay hundreds of millions of dollars to state health insurance programs after admitting to a years-long kickback scheme to promote its panel of HIV medications. The California-based drug company reached a $202 million settlement with a coalition of 49 states led by New York for incentivizing doctors to prescribe its HIV meds with hundreds of thousands of dollars in payments,

The World Health Organization on Monday recommended Gilead's lenacapavir, a twice-yearly injection, as a tool to prevent HIV infection. The recommendation, issued at the International AIDS Conference in Kigali,

Freda Jones, founder of LOTUS, empowers women living with HIV in Atlanta through a peer-led support group. Peer support is crucial for HIV care.

A new study explores how healthcare providers can effectively implement Apretude for HIV pre-exposure prophylaxis (PrEP) among Black women.

ViiV Healthcare has announced steps to widen access to a sought-after HIV medicine in low- and middle-income countries, reflecting ongoing pressure to respond to criticism.

Lenacapavir has been incredibly promising in trials and now the World Health Organisation have officially recommended the drug for HIV prevention. Smitha Mundasad explains the difference this bi-annual injection could make in the fight against HIV.

This story was originally published by The Institute for Public Service Reporting Memphis. Healthcare providers across Tennessee are scrambling to find new funding for HIV prevention following the loss of a critical federal grant.

A landmark breakthrough in HIV prevention — a scientific feat decades in the making — received final approval from the Food and Drug Administration last month. Gilead Sciences’ lenacapavir is so effective that global health leaders had started to cautiously talk about the end of an epidemic that continues to kill more than 600,000 people each year.